Carmustine: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Carmustine. Educational only — not medical advice.
Labeled uses
Carmustine for injection, USP is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.
Source: FDA labeling via NIH DailyMed (set 0bdd91e1…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.